文献速递免疫规划传染病防控与疫情报告

芬兰疫苗适龄儿童中十价肺炎球菌结合疫苗有效性的三种平行研究设计评估

Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland.
PubMed 文献 · Vaccine · 2019-11-29

芬兰于2010年9月将十价肺炎球菌结合疫苗(PCV10)纳入国家疫苗接种计划。研究基于全国人群监测和疫苗接种登记数据,对疫苗适龄儿童随访至2018年底,采用全队列、巢式病例对照和间接队列三种设计估计个体水平疫苗有效性(VE)。三种设计对PCV10血清型侵袭性肺炎球菌疾病(IPD)的VE估计一致且较高,对PCV10相关血清型VE中等,对非PCV10相关血清型VE为负但包含零效应。

要点

  • PCV10血清型IPD的VE在全队列、巢式病例对照和间接队列设计中分别为93%、98%和100%。
  • PCV10相关血清型IPD的VE分别为46%、51%和78%,置信区间较宽。
  • 非PCV10相关血清型VE为负但包含零效应;所有IPD的VE随时间下降。

核心结论

  • 三种设计提供的VE估计相互一致,全队列设计通常最精确。
  • PCV10在纳入国家疫苗接种计划后的第一个十年内对接种儿童的PCV10血清型IPD提供持续高VE。

研究设计与样本

  • 基于芬兰全国人群监测的侵袭性肺炎球菌疾病(IPD)数据和疫苗接种登记数据。
  • 疫苗适龄儿童为2010年6月或之后出生,从6月龄随访至2018年底(年龄6-102月)。
  • 采用全队列、巢式病例对照和间接队列三种平行设计估计VE,并调整年龄组、性别和日历年。

主要发现

  • 针对PCV10血清型IPD的VE:全队列93%(95%可信区间87-97%),巢式病例对照98%(90-100%),间接队列100%(98-100%)。
  • 针对PCV10相关血清型IPD的VE:全队列46%(-13-72%),巢式病例对照51%(-24-79%),间接队列78%(-7-97%)。
  • 针对非PCV10相关血清型IPD的VE为负但包含零效应:全队列-67%(-711-52%),巢式病例对照-77%(-929-59%)。
  • 针对所有IPD的VE:全队列54%(24-71%),巢式病例对照61%(26-79%)。
  • 随时间推移,针对PCV10血清型IPD的VE保持稳定,但针对所有IPD的VE下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Programme (NVP) in 9/2010. We estimated the individual-level effectiveness (VE) of PCV10 in children during eight years of vaccine implementation. METHODS: Data on invasive pneumococcal disease (IPD) were collected from national, population-based surveillance, and vaccination status from the vaccination register. Vaccine-eligible children were followed from six months of age until end of 2018 (born 6/2010 or later, ages 6-102 months). VE was estimated with three parallel approaches: full cohort, nested case-control and indirect cohort designs adjusting with age-group, sex and calendar year. RESULTS: VE against PCV10 serotype IPD was estimated at 93% (95% credible interval 87-97%), 98% (90-100%) and 100% (98-100%), and against PCV10-related serotypes at 46% (-13-72%), 51% (-24-79%), and 78% (-7-97%), with the full cohort, nested case-control, and indirect cohort designs, respectively. The estimated VE against non-PCV10-related (neither PCV10 nor PCV10-related) serotypes was negative but included zero effectiveness (full cohort VE -67%, -711-52%; nested case-control VE -77%, -929-59%). VE against all IPD was estimated with these two methods at 54% (24-71%) and 61% (26-79%). Over time, VE against PCV10 IPD remained stable but VE against all IPD decreased. DISCUSSION: All designs provided estimates that were concordant with each other, but those with the full cohort design were usually the most precise. PCV10 offered sustained high VE against PCV10-serotype IPD on vaccinated children during the first decade after introduction into the programme.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rinta-Kokko H, Auranen K, Toropainen M, et al. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland. Vaccine. 2019. PMID: 31791813. doi:10.1016/j.vaccine.2019.11.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。